Crossmark

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Crossref DOI link: https://doi.org/10.1186/s13045-018-0693-2

Published Online: 2019-01-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tang, Bixia

Yan, Xieqiao

Sheng, Xinan

Si, Lu

Cui, Chuanliang

Kong, Yan

Mao, Lili

Lian, Bin

Bai, Xue

Wang, Xuan

Li, Siming

Zhou, Li

Yu, Jiayi

Dai, Jie

Wang, Kai

Hu, Jinwei

Dong, Lihou

Song, Haifeng

Wu, Hai

Feng, Hui

Yao, Sheng

Chi, Zhihong

Guo, Jun https://orcid.org/0000-0003-1759-0986
Funding

Funding for this research was provided by:

Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support (ZYLX201603)

National Science &Technology Major Project “Key New Drug Creation and Manufacturing Program” (2015ZX09102017)
License Information

Text and Data Mining valid from 2019-01-14
More Information

Article History

Received: 31 August 2018

Accepted: 25 December 2018

First Online: 14 January 2019

Ethics approval and consent to participate

: The study was approved by regulatory and independent ethics committees at Beijing Cancer Hospital and done in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent before study entry.

: All patients provided written informed consent for publication.

: Kai Wang and Jinwei Hu are employees of OrigiMed, Hai Wu, Hui Feng, and Sheng Yao are employees of Shanghai Junshi Biosciences Co. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below